Abstract |
5-Fluorouracil was introduced in the early 1960s as a topical chemotherapeutic agent and has become increasingly accepted because of its efficacy, economy, and relative absence of side effects in treating many pre-cancerous conditions, certain benign and malignant tumors, and dermatoses. This paper addresses the use of topical 5-fluorouracil in the management of cholesteatoma and unwanted mucus-secreting cells. A retrospective study has suggested a very impressive efficacy of topical 5-fluorouracil in the management of cholesteatoma and, to a lesser degree, control of hyper-mucus-secreting cells at locations in the middle ear and mastoid. The use of topical 5-fluorouracil in the management of hyperkeratosis, cholesteatoma in the middle ear and mastoid, and in the external canal has been almost 100% effective with very few side effects. In the management of hyper-mucous-secreting cells, 5-fluorouracil has a success rate of approximately 50%.
|
Authors | M F Smith |
Journal | The Laryngoscope
(Laryngoscope)
Vol. 95
Issue 10
Pg. 1202-3
(Oct 1985)
ISSN: 0023-852X [Print] United States |
PMID | 4046704
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Child
- Cholesteatoma
(drug therapy)
- Ear Diseases
(drug therapy)
- Ear, Middle
(metabolism)
- Fluorouracil
(administration & dosage, therapeutic use)
- Humans
- Middle Aged
- Mucus
(metabolism)
|